New injection may replace radiation for eye cancer, offering fewer side effects
NCT ID NCT06190301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a direct injection of the drug rituximab into eye tumors works as well as standard radiation therapy for a slow-growing eye lymphoma (MALT lymphoma). The goal is to control the disease with fewer complications. About 108 adults with early-stage eye lymphoma will be randomly assigned to one of the two treatments and followed for 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OCULAR ADNEXAL MALT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Ophthalmic Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••